The pharmaceutical market in Brazil, Mexico and Venezuela was valued at USD26, USD9.4 and USD7.2 billion respectively by IMS Health (a leading provider of information, services and technology for the healthcare industry) as at June 2012. Brazil is one of the top 10 pharmaceutical markets in the world and Mexico one of the top 20.
Aspen supplies a range of quality affordable products through its affiliate companies in Argentina, Brazil, Mexico and Venezuela as well as across the rest of Latin America in countries such as Chile, Columbia, Ecuador and the Carricam territories.
Aspen’s product offering covers numerous therapeutic categories such as the central nervous system, cardiovascular, urinary and endocrine. The leading brands in Latin America include Calman, Eutropin, Insunorm, Suplan, Sedopan, Rosucrest, Sildenafil, Licovit, Cidorix and Triavit. Manufacture of these products takes place at Aspen’s facilities in Vitória in Brazil and Toluca in Mexico as well as through Aspen’s extended sourcing network.
Aspen has shifted its business focus in Latin America from the public to the private sector, which now represents more than 80% of its total sales which amounted to ZAR 1 billion for the year ended 30 June 2012.
Aspen sees Latin America as one of its key strategic regions with significant growth potential within the Group, and continues to seek opportunities to establish a greater presence in other Latin American countries. The Latin American region also has a strong product pipeline to stimulate organic growth.